News – Page 1082 – Endpoints News

Ardelyx scraps PhIII drug after researchers raise a safety issue for hyperkalemia patients

8 years ago

Stanford trial points to a new CAR-T drug, spotlighting a fresh target for next-gen cell therapies

8 years ago

After unexpected tie, Amsterdam wins 'coin toss' for new EMA HQ

8 years ago

Promentis closes $26M round and enters clinic; PellePharma gets breakthrough/orphan status; Shire appoints Dittrich ...

8 years ago

The top 10 hit parade of biopharma licensing deals for 2014-2017

8 years ago

Bayer AG taps PeptiDream in billion-dollar deal

8 years ago

FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency

8 years ago

Acorda writes off $363M drug, axing PhIII Parkinson’s drug in the wake of 5 patient deaths

8 years ago

Roche shares surge as a double-shot win in I/O and hemophilia raises blockbuster expectations

8 years ago

Fearless: Julian Adams looks to steer Gamida Cell through PhIII, an IPO and a market launch

8 years ago

ScPharmaceuticals raises $90M in IPO with heart failure drug on deck

8 years ago

UK research campus expands; FDA clears NGS test for tumors; Orphazyme raises €80 million IPO

8 years ago

Pfizer reshuffles top ranks with Albert Bourla as COO; Intra-cellular nabs Novartis vet Andrew Satlin as CMO

8 years ago

Annalisa Jenkins' next career chapter takes her back to Europe

8 years ago

A go-go FDA is opening up the fast lane to regenerative med approvals

8 years ago

Struggling Oncolytics Biotech signs $86.6M Asia deal with China's Adlai Nortye

8 years ago

Booming Regeneron gets the green light for a major expansion

8 years ago

What's a successful failure? Atlas' Booth sounds taps for Merck-backed Quartet Medicine

8 years ago

FDA clears next-gen tumor sequencing test from Memorial Sloan Kettering

8 years ago

The Pentagon's compromise: drug approvals to remain in FDA's hands

8 years ago

In blow to Shire, Roche bags an FDA OK for its blockbuster hemophilia A prospect

8 years ago

Merck partners up on T-cell tech platform in $374M autoimmune deal; Turnstone taps BMS vet Mike Burgess for top R&D ...

8 years ago

Let the jousting begin: Which top biopharma companies are looking to make a splash at ASH?

8 years ago

Arsanis prices $40M IPO for infectious disease work

8 years ago

First page Previous page 1079 1080 108110821083 1084 1085 Next page Last page